NCT04119102PHASE4Recruiting
Duobrii in Combination With Biologics
Psoriasis Treatment Center of Central New Jersey
Start Date
10/14/2019
Completion Date
9/1/2020
Summary
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Detailed Description
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
1. Male or female adult ≥ 18 years of age;
2. Diagnosis of chronic plaque-type
3. Psoriasis affecting 2%-10% BSA
4. Patient is being treated with biologic therapy for a minimum of 24 weeks
5. Able and willing to give written informed consent prior to performance of any study-related procedures
Exclusion Criteria:
1. Psoriasis affecting ˂2% or \>10% BSA
2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks
3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
4. Has previously used DUOBRII
Interventions
DRUG
Duobrii
Conditions
Psoriasis
Locations
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey 08520
United States